• vcard
  • Education
    • LL.M., Loyola University Chicago School of Law, 2007, Health Law; CALI Award
    • J.D., UIC John Marshall Law School, 2006, Dean's List; Moot Court Council; Dean Herzog Moot Court Competition First Place Overall
    • B.A., University of Illinois, 2003, Economics

Kyle Vasquez maintains a national health care practice and provides pragmatic legal and compliance support to a wide range of health care clients. He utilizes his background in health law and his prior experience as a health care consultant to develop creative approaches to complex issues. Kyle provides 340B drug pricing program, reimbursement, licensing/certification, DEA and other regulatory support to a broad set of health care entities including academic medical centers, multi-hospital health systems, community hospitals, FQHCs, institutional and retail pharmacies, and physician practices, among others.

Kyle’s areas of focus include:

  • Providing 340B regulatory, compliance, audit, repayment, self-disclosure, litigation and contract support to Covered Entities, Contract Pharmacies, and other key stakeholders.
  • Advising on multi-state telehealth and telepharmacy matters, including assisting with state licensing, controlled substance and DEA obligations. 
  • Counseling various provider types on complex healthcare reimbursement and cost report matters, including Medicare, Medicaid, and private payor reimbursement, to ensure consistent cash flow and compliance with applicable rules.
  • Assisting multiple provider/supplier types with provider enrollment, licensing and certification matters.
  • Structuring and negotiating a variety of transactions, including provider-based conversions, physician practice acquisitions, joint ventures, joint operating agreements, mergers, and acquisitions.
  • Assisting providers with administrative appeals, reconsideration requests, and other litigation strategies regarding adverse government agency findings.
  • Assisting with self-disclosures, government audits, and appeals of audit findings.
  • Represented 340B Covered Entities in matters against drug manufacturers to successfully obtain access to limited distribution drugs at the 340B ceiling price, and represented 340B Covered Entities in their pursuit of refunds from manufacturers that previously charged prices that exceeded the statutory 340B ceiling price
  • Advised several academic medical centers on telehealth matters for COVID and post-COVID operations, including an analysis of state and federal controlled substance rules and registration requirements for multi-state operations
  • Assisted accountable care organization entity with development of strategic 340B model
  • Represented Section 318 clinic in litigation related to 340B drug pricing agreements
  • Assisted 340B Covered Entity with regulatory considerations when developing transplant outreach sites
  • Assisted with development of new hospital cancer center participating in the 340B program including assistance with definitive documents related to partnership with local oncology group
  • Assisted academic medical center with the development of an in-house specialty pharmacy
  • Successfully represented several 340B Covered Entities during Office of Pharmacy Affairs 340B audits and mitigated audit findings; prepared and implemented OPA-approved Corrective Action Plans and assisted Covered Entities with manufacturer repayments
  • Performed independent 340B audit readiness reviews of a number of 340B Covered Entities and developed internal Corrective Action Plans
  • Defended hospital in whistleblower false claims act action related to 340B matters
Related News

Past Events